Last reviewed · How we verify
Nandrolon Phenylpropionate (NANDROLONE PHENPROPIONATE)
Nandrolone Phenylpropionate works by binding to androgen receptors in the body, mimicking the effects of male hormones.
Nandrolone Phenylpropionate (NANDROLONE PHENPROPIONATE) is a small molecule androgen developed by ORGANON USA INC in 1959. It targets the androgen receptor and is used to treat various conditions. As an off-patent medication, it is available as a generic product. The commercial status of Nandrolone Phenylpropionate is off-patent, with one generic manufacturer. Key safety considerations include its potential for androgenic side effects.
At a glance
| Generic name | NANDROLONE PHENPROPIONATE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Androgen |
| Target | Androgen receptor, Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
| First approval | 1959 |
Mechanism of action
Imagine your body has locks on the cells that control muscle growth and bone density. Nandrolone Phenylpropionate has a key that fits into these locks, allowing it to turn on the signals that promote muscle growth and bone density. This helps to treat conditions where these signals are low.
Approved indications
Common side effects
Key clinical trials
- Peri-Operative Testosterone Administration in Primary Hip Arthroscopy (PHASE4)
- Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty (PHASE4)
- Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet (PHASE2)
- Nandrolone Decanoate in the Treatment of Telomeropathies (PHASE1,PHASE2)
- Assessment of Mechanisms of Improved Wound Healing (PHASE2,PHASE3)
- Anabolic Steroid and Propranolol in Paediatric Burn (NA)
- A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss (PHASE1)
- Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nandrolon Phenylpropionate CI brief — competitive landscape report
- Nandrolon Phenylpropionate updates RSS · CI watch RSS
- Merck & Co. portfolio CI